Re Supplier Agreement

Fulcrum Pharma PLC
29 March 2004


For Immediate Release                                              29 March 2004

                               FULCRUM PHARMA PLC

                  Signs Second Preferred Supplier Arrangement
                        A three year agreement with BTG


Hemel Hempstead, UK, 29 March 2004: Fulcrum Pharma PLC (AIM: FUL), the drug
development and strategic outsourcing services company, is pleased to announce
the signing of a preferred supplier arrangement with BTG (LSE: BGC), the global
technology commercialisation company, in which Fulcrum Pharma will provide
pre-clinical and clinical development services over a three year period.

The preferred supplier arrangement, under which Fulcrum Pharma will receive fees
for the services it provides, will cover BTG's therapeutic areas of Oncology and
Ageing & Neuroscience.

Fulcrum Pharma already provides development services to BTG for the on-going
clinical trial of BGC 9331, a potential new treatment for gastric and other
cancers.

Jon Court, chief executive of Fulcrum Pharma, said: 'We are delighted to have
been selected by BTG as its preferred provider of pre-clinical and clinical
development services. BTG and Fulcrum have been working successfully together
since 2002 and this agreement represents a broadening of this relationship.

'We look forward to supporting BTG in its quest to build a strong portfolio of
drugs for out-licensing.'

BTG anticipates that the first two programmes under the preferred supplier
arrangement will be BGC 945, a new and highly selective potential treatment for
cancers, and BGC 20-1259,  for the treatment of Alzheimer's disease.

Anthony V. Lando, BTG's chief operating officer, said: 'BTG is building a strong
out-licensing portfolio of drugs in Oncology and Ageing & Neuroscience and we
are willing to back our judgment by investing in their development. Our
relationship with Fulcrum gives BTG access to high quality drug development
services.'

The agreement with BTG marks the second preferred supplier arrangement signed by
Fulcrum Pharma. In December last year, the Company signed a three year preferred
supplier arrangement with Addex Pharmaceuticals SA, the Swiss pharmaceutical
company.


For further information, please contact :

Fulcrum Pharma PLC
Jon Court, Chief Executive                                08707 107152
Geoffrey Smith, Finance Director                          08707 104501

BTG
Lorraine Jones                                            020 7575 1622

Buchanan Communications (for Fulcrum Pharma)
Mary-Jane Johnson                                         020 7466 5000


Notes to Editors:

About Fulcrum Pharma

Fulcrum Pharma plc is an independent, drug development company that is the first
to offer global virtual drug development and strategic outsourcing services to
the pharmaceutical industry.  The Company has expertise in the design, execution
and delivery of drug development programmes and relies on state of the art
information technology and infrastructure in the supply of its services.

Through Fulcrum's services to its clients, the Directors believe that there is
the capacity to deliver products faster and more efficiently to the global
pharmaceutical market. Fulcrum does this by using its skills in the design of
drug programmes that deliver the necessary information for decision-making and
product registration. In so doing, Fulcrum works closely with its clients to
meet their strategic R&D goals.

Fulcrum Pharma is listed on the Alternative Investment Market of the London
Stock Exchange having successfully floated in March 2000.


About BTG

BTG finds, develops and commercialises emerging technologies in the life and
physical sciences.  These innovations are protected by a strong portfolio of
intellectual property that BTG develops and enhances.  BTG then captures the
value in these technologies through licensing and venturing activities.  From
the origins of its business in 1949, BTG has commercialised major innovations
such as Magnetic Resonance Imaging (MRI), recombinant factor IX blood-clotting
protein, Campath(R) (alemtuzumab) and Multilevel Cell (MLC) memory.  BTG is
quoted on the London Stock Exchange under the symbol 'BGC' and operates from
offices in London and Philadelphia, with representation in Tokyo.  BTG operates
through wholly owned subsidiaries, BTG International Ltd and BTG International
Inc in the UK and USA, respectively.  Further information on BTG can be found at
www.btgplc.com


                      This information is provided by RNS
            The company news service from the London Stock Exchange